Explore the Agenda
7:10 am Check-In & Coffee
Settle in with morning refreshments while enjoying early, informal access to your peers, collaborators and industry counterparts. Reconnect, align interests from the outset, and identify who you’d like to engage with further across the next two days of the event.
Developing CAR & TCR Innovations to Deliver Clinical Impact Across Expanding Indications
8:10 am Program Directors’ Welcome Address
8:15 am Chair’s Opening Remarks
8:20 am Industry Leader’s Fireside Chat: Evaluating the CAR & TCR Therapeutic & Commercial Landscape to Propel Advanced Cell Therapy Innovation, Expand Treatment Options & Ensure Positive Commercial Outcomes
- Highlighting evolving modality innovations and industry shifts to demonstrate how rapid scientific and technological progress is enhancing treatment accessibility and reshaping the cell therapy landscape
- Aligning clinical development, scalability and patient access strategies to accelerate commercialization pathways across advanced cell therapy modalities
- Discussing post-approval reimbursement policies and strategies to ensure long-term commercial success
- Predicting cell therapy evolution through 2026 and beyond to provide strategic and commercial foresight
8:55 am Delivering Commercial-Ready Cell Therapies at Scale through a Global Network of Smart Factories
- Case study: successful manufacturing of a clinical-stage CAR-T drug product using the Cellares Cell Shuttle
- Breaking the QC bottleneck with high-throughput, digitally integrated release testing via Cell Q
- Standardizing automation-native facility design across the US, EU, and Japan
9:25 am Proving Durable Autoimmune Responses to Expand Safety, Access & Clinical Impact
9:50 am Developing the UltraCAR-T® Platform to Expand Patient Access & Drive Scalable Manufacturing in Next-Generation Cell Therapy
10:15 am Morning Break & Networking
Take the opportunity to meet peers, review partners and take part in pre-organized meetings scheduled in the meeting app, then recharge with light refreshments before heading into your preferred track.
Discovery & Translation Track
Advance Novel Modalities & Biomarkers with AI, In Vivo Innovation & Translational Relevance
This track is tailored for experts in: R&D, Discovery, Translation, Preclinical
Designing CARs & TCR Constructs to Enhance Treatment Functionality in Solid Tumors
11:15 am Next-Generation TCR Engineering: Integrating Co-Stimulation & Novel Antigen Targeting to Expand the Reach of T-Cell Therapies
- Engineering next generation TCR constructs with built in co-stimulatory signaling to deliver dual functionality through a single molecule
- Reducing reliance on additional receptors, knockouts, or complex modifications to improve manufacturability and clinical durability
- Targeting novel solid tumor antigens such as ROPN1 in triple negative breast cancer to address high unmet need and expand the reach of T-cell therapies into new indications
11:40 am Reserved for Agilent Technologies
12:10 pm Engineering Gated CAR-Ts to Enhance Target Specificity & Combat the Solid Tumor Microenvironment
- Designing logic gated CAR-T to overcome ontarget off-tumor toxicities in solid tumors
- Utilizing logic in vivo delivery platforms for logic gated CAR-T cells
- Discussing how logic gating enables armoring to enhance potency and overcome suppressive TME
12:35 pm Reserved for Miltenyi Biotec
1:05 pm Lunch Break & Networking
Private Lunch Hosted by PBS Biotech
Enjoy lunch as you spark new discussions, build relationships that can drive impact throughout the summit.
Strengthening Cell Therapy Translation through Predictive Models, Safety Insight & Regulatory Alignment
2:05 pm Targeting Prostate Cancer: Arsenal Bio’s Programmable Circuit T (PCT) Cell Platform & the Development of AB-3028
- Strengthening CAR-T selectivity with logic gating to safely target solid tumors
- Enhancing CAR-T potency with modular engineering to endure the tumor microenvironment
- Enabling translational readouts to validate cell therapy module function in the clinic
2:30 pm Panel Discussion: Aligning Preclinical Model Selection with Regulatory Expectations to Improve Translation & Approval Confidence
- Evaluating mouse and non-human primate model translatability to improve clinical predictability
- Comparing model suitability across therapy types to highlight strategic differences that reduce regulatory risk
- Discussing gaps between required regulatory model data and biopharma efficacy needs to align development strategies with translational approval
3:30 pm IMANs as an Example of Innate Cells’ Direct & Indirect Therapeutic Activity
- Demonstrating innate cell types including IMANs direct therapeutic activity
- Improving and broadening IMAN activity with CARs
- Showing IMANs help CAR-T, CAR-NK and other cell therapies work when they don’t
3:55 pm Afternoon Break & Poster Session
Submit a scientific poster to showcase your findings to the industry’s market leaders to ignite discussion, test emerging theories and connect for future opportunities. Also take advantage of the opportunity to win the 11th CAR-TCR Summit Poster Prize, selected by our esteemed scientific advisory board. The selected poster winner will have the opportunity to give a 10-minute presentation to the full audience in this dedicated break, providing an opportunity to share key findings, elevate visibility and engage with key experts in this high-impact forum.
Plenary Sessions
Advancing T-Cell Therapy Evolution to Enable Durable Solid Tumor Impact & Accelerate Clinical Translation
5:00 pm Reserved for Lonza
5:30 pm Advancing Autologous Therapies to Enable Durable Solid Tumor Therapy
5:55 pm Establishing Durable Impact on Tumors through Phase 1 Evidence: Bench to Bedside & Back
6:20 pm CAR-TCR Connect
Wrap up day one with a relaxed drinks reception designed to turn great sessions into even better conversations. Reconnect with speakers whose ideas sparked your thinking, swap questions, and insights with peers, and explore topics beyond presentation slides.
Location: The Pavillion